Fluorodeoxyglucose-PET in Melanoma and Soft-Tissue Sarcoma: Current Applications, Challenges, and Future Directions

Fluorodeoxyglucose PET/computed tomography plays a central role in the management of melanoma and soft-tissue sarcoma by enabling comprehensive metabolic imaging for staging, response assessment, and prognostication. It improves detection of distant disease and guides clinical decision-making, particularly in advanced stages. Quantitative PET parameters enhance prognostic evaluation, while emerging applications such as radiomics and artificial intelligence are shaping its role in precision oncology. Careful interpretation is required to account for limitations, including false-positive findings and atypical response patterns associated with immunotherapy.